<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etiology, clinical manifestations, and diagnosis of vascular dementia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etiology, clinical manifestations, and diagnosis of vascular dementia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Etiology, clinical manifestations, and diagnosis of vascular dementia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric E Smith, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clinton B Wright, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H337964271"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vascular dementia refers to any dementia that is primarily caused by cerebrovascular disease or impaired cerebral blood flow and falls within the spectrum of vascular cognitive impairment (VCI), a syndrome that includes all cognitive disorders in which cerebrovascular disease or impaired cerebral blood flow is a contributing causative factor. Vascular dementia is the second most common form of dementia, only exceeded by Alzheimer disease (AD) in terms of prevalence and incidence [<a href="#rid1">1</a>]. </p><p>Neuroimaging has vastly improved the ability to detect and diagnose stroke and silent manifestations of cerebrovascular disease that impair cognition [<a href="#rid2">2</a>]. However, neuroimaging can also detect cerebrovascular brain injury in asymptomatic older adults [<a href="#rid3">3</a>]; therefore, the mere presence of any cerebrovascular brain injury is not sufficient to diagnose vascular dementia. Clinical features and the location and severity of cerebrovascular brain injury detected on brain imaging must be used to make a clinical judgment whether cerebrovascular disease is sufficient to cause vascular dementia. As with the later-life neurodegenerative diseases such as AD, vascular neuropathology becomes very common with advanced aging and is often accompanied by other neuropathologies. </p><p>This topic will review the epidemiology, clinical features, evaluation, and diagnosis of vascular dementia in adults. Treatment and prevention of vascular dementia are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia"</a>.) </p><p class="headingAnchor" id="H2906402946"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H55433634"><span class="h2">Vascular dementia</span><span class="headingEndMark"> — </span>Vascular dementia refers to any dementia that is primarily caused by cerebrovascular disease or impaired cerebral blood flow, or in which cerebrovascular disease or impaired cerebral blood flow is a contributing causative factor. Vascular dementia is typically recognized in either of two clinical scenarios [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A clinically diagnosed stroke is followed by dementia; or</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain imaging identifies vascular brain injury in a patient with dementia but without a clinical history of stroke</p><p></p><p>Clinical features and the location and severity of cerebrovascular brain injury detected on brain imaging must be used to make a clinical judgment whether cerebrovascular disease is sufficient to cause vascular dementia. (See <a class="local">'Evaluation'</a> below and <a class="local">'Diagnosis'</a> below.)</p><p>It is important to recognize that vascular dementia is a syndrome, not a disease. Vascular dementia may be caused by any cerebrovascular or cardiovascular disease that leads to vascular brain injury or dysfunction, including any of the causes of ischemic stroke (eg, cardioembolism, large artery atherosclerotic disease, cerebral small vessel diseases) or hemorrhagic stroke. The diagnosis of vascular dementia is not complete until the underlying cerebrovascular or cardiovascular diseases have been identified, as this information is needed to design a plan for secondary prevention of future vascular brain injury. (See  <a class="medical medical_review" href="/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H1942956039"><span class="h2">Vascular cognitive impairment</span><span class="headingEndMark"> — </span>The term "vascular cognitive impairment" (VCI) has been proposed by the writing group for National Institute of Neurological Disorders and Stroke (NINDS)-Canadian Stroke Network VCI harmonization standards and the American Heart Association to refer to "cognitive impairment that is caused by or associated with vascular factors" [<a href="#rid5">5</a>]. The VCI concept encompasses dementia as well as milder forms of impairment, including mild cognitive impairment (MCI) caused by cerebrovascular disease.</p><p>Similar to vascular dementia, VCI is a syndrome that may be caused by any cerebrovascular or cardiovascular disease that leads to vascular brain injury or dysfunction.</p><p class="headingAnchor" id="H164910002"><span class="h2">Multiple-etiology or mixed dementia</span><span class="headingEndMark"> — </span>Autopsy studies suggest that pure vascular dementia is less common than the situation in which vascular dementia is only one of the etiologies of multiple-etiology (also termed "mixed") dementia [<a href="#rid6">6</a>]. Alzheimer neuropathology, with characteristic beta-amyloid plaques and tangles, is the most common co-occurring pathology with vascular dementia.</p><p>Multiple-etiology dementia may be diagnosed clinically when a patient with vascular dementia also meets consensus diagnostic criteria for another neurodegenerative disorder such as Alzheimer disease (AD). (See  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease"</a> and  <a class="medical medical_review" href="/d/html/16575.html" rel="external">"Epidemiology, pathology, and pathogenesis of Alzheimer disease", section on 'Cerebrovascular disease'</a>.) </p><p class="headingAnchor" id="H3815958232"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Quantifying the contribution of vascular disease to dementia is challenging because it is frequently seen in asymptomatic older adults as well as in persons with dementia, and it frequently coexists with other neurodegenerative pathologies of aging such as Alzheimer disease (AD) [<a href="#rid1">1</a>].</p><p>Thus, there are opportunities for misclassification (eg, misclassifying multiple-etiology dementia with a vascular component as pure AD). Misclassification can be reduced with the use of neuroimaging to detect clinically unrecognized vascular brain injury [<a href="#rid2">2</a>], with the use of biomarkers of the AD pathophysiologic process to detect AD pathology during life [<a href="#rid7">7</a>], or with neuropathologic confirmation. </p><p class="headingAnchor" id="H495150460"><span class="h2">Incidence and prevalence</span><span class="headingEndMark"> — </span>Vascular disease is a cause or contributor in 25 to 50 percent of cases of dementia, and vascular dementia is the second most common type of dementia in clinic- and population-based studies [<a href="#rid1">1,6</a>].</p><p>Clinicopathologic studies from dementia specialty clinics indicate that pure vascular dementia is relatively uncommon, accounting for approximately 10 percent of all dementia cases [<a href="#rid6">6,8</a>]. Multiple-etiology dementia with a vascular component, most often in combination with AD, is more common and accounts for approximately 30 to 40 percent of all dementia cases [<a href="#rid6">6,8</a>].</p><p>In the population-based Medical Research Council Cognitive Function and Aging Study (MRC CFAS) neuropathology study, cerebral small vessel disease accounted for 12 percent of dementia risk, cerebral amyloid angiopathy (CAA) accounted for 7 percent of risk, and multiple vascular pathologies accounted for 9 percent of risk [<a href="#rid9">9</a>]. In the Baltimore Longitudinal Study on Aging, cerebral small vessel disease accounted for 33 percent of dementia risk [<a href="#rid10">10</a>]. </p><p>The estimated prevalence of vascular dementia among individuals 65 years of age and older is 1.6 percent and rises with increasing age [<a href="#rid11">11</a>]. Among the participants 60 years or older recruited to the Framingham Heart Study from 2004 to 2008, 0.4 persons out of 100 (95% CI 0.2-0.7) developed vascular dementia over a five-year period [<a href="#rid12">12</a>].</p><p>There are far fewer studies of the prevalence of vascular mild cognitive impairment (MCI) and the risk of progressing from vascular MCI to dementia. A community-based study of persons with MCI found that 16 percent had infarcts as their sole pathology, while 17 percent had both infarcts and AD pathology [<a href="#rid13">13</a>]. A population-based study found that 15 percent of patients who had cognitive impairment but not dementia (CIND) were clinically diagnosed with vascular disease as the cause, but autopsy confirmation was not available [<a href="#rid14">14</a>]. The same population-based study found that 46 percent of patients with vascular CIND had progressed to dementia by five years, with approximately half of the new dementia cases attributed to progressive or recurrent cerebrovascular disease [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3518094699"><span class="h2">Risk factors in the general population</span><span class="headingEndMark"> — </span>Because stroke can cause vascular dementia, risk factors for stroke are also risk factors for vascular dementia in the general population. In population-based studies, the major risk factors for vascular dementia include [<a href="#rid11">11,16-24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated total cholesterol levels</p><p class="bulletIndent1"><span class="glyph">●</span>Lower physical activity</p><p class="bulletIndent1"><span class="glyph">●</span>Low or high body mass index</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary artery disease</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation</p><p></p><p>There have been marked improvements in population vascular risk factor control over the last 40 years, with substantial decreases in stroke incidence and mortality [<a href="#rid25">25</a>]. A similar trend in vascular dementia incidence was identified in the population-based Framingham Heart Study, in which the five-year incidence of vascular dementia dropped from 0.8 to 0.4 per 100 persons from the five-year period between 1977 and 1983 to the period between 2004 and 2008 [<a href="#rid12">12</a>]. Better vascular risk factor control and better prevention and treatment of stroke were implicated by the study authors as potential reasons for the decline.</p><p>Factors related to cognitive reserve probably play a role in determining risk of vascular dementia, but the role of cognitive reserve has been understudied in vascular dementia compared with AD. Cognitive reserve refers to the brain's ability to compensate for a given level of pathology. Factors such as higher education and occupational attainment have been associated with lower risk for cognitive decline in the setting of cerebrovascular pathology [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H3376643192"><span class="h2">Risk factors for poststroke dementia</span><span class="headingEndMark"> — </span>Dementia is common both before and after stroke. In a systematic review that identified 22 hospital-based stroke cohort studies, 14 percent of patients hospitalized with stroke had a preceding history of dementia, and 12 percent of patients without prestroke dementia had dementia following a first stroke [<a href="#rid27">27</a>].</p><p>Risk factors for new dementia after stroke include [<a href="#rid27">27,28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prestroke factors (advanced age, race, low education, diabetes, and atrial fibrillation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stroke factors (intracerebral hemorrhage, aphasia, left hemisphere location, and multiple or recurrent strokes)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stroke complications (incontinence, confusion, or seizures)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower brain reserve (brain imaging evidence of leukoaraiosis, general atrophy, medial temporal lobe atrophy, and beta-amyloid deposition)</p><p></p><p class="headingAnchor" id="H3071685303"><span class="h1">ETIOLOGY AND PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Vascular dementia is caused by diseases of the cerebral vasculature and of the cardiovascular system, including hypoperfusion and embolism from the heart [<a href="#rid29">29</a>]. The dominant paradigm is that these diseases disrupt normal brain function and cause cognitive impairment through brain ischemia or loss of vascular integrity with hemorrhage.</p><p>Any cause of ischemic stroke (cardioembolism, large artery atherosclerosis, cerebral small vessel disease), intracerebral hemorrhage, or subarachnoid hemorrhage can cause vascular dementia if the resulting brain injury is severe enough (<a class="graphic graphic_table graphicRef118574" href="/d/graphic/118574.html" rel="external">table 1</a>) [<a href="#rid30">30</a>].</p><p>Aside from clinical stroke, cerebral small vessel diseases play an outsized role in the burden of vascular dementia. Although only accounting for 20 to 25 percent of stroke, cerebral small vessel disease is the most common neuropathologic correlate of both vascular dementia and multiple-etiology ("mixed") dementia with a vascular component [<a href="#rid31">31</a>]. Frequently, cerebral small vessel disease is clinically unrecognized until it is detected on brain imaging or neuropathology.</p><p>The main types of cerebral small vessel disease are [<a href="#rid32">32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Arteriolosclerosis – Arteriolosclerosis due to aging, hypertension, and conventional stroke-related vascular risk factors is the most common type of cerebral small vessel disease. The walls of small arteries and arterioles exhibit changes such as thickening, hyalinization, lipohyalinosis, microaneurysm formation, and loss of vascular integrity with cracking and perivascular hemosiderin deposits [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Arteriolosclerotic cerebral small vessel disease prominently affects subcortical brain regions including the basal ganglia and corona radiata [<a href="#rid32">32</a>]. This is presumed to be because there are fewer subcortical collateral vessels compared with the rich collateralization of the cerebral cortex [<a href="#rid34">34</a>]. As a result, patients with arteriolosclerotic cerebral small vessel disease typically have multiple lacunes or extensive, confluent white matter lesions as the pathogenic basis for their symptoms [<a href="#rid34">34</a>]. Synonyms for this vascular dementia syndrome include Binswanger disease [<a href="#rid35">35</a>] and subcortical ischemic vascular dementia [<a href="#rid36">36,37</a>]. Although the subcortical changes are obvious, there may be subtler manifestations in the cortex including microinfarcts [<a href="#rid38">38</a>] and secondary neurodegeneration with apoptosis, leading to cortical thinning [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral amyloid angiopathy (CAA) – CAA is the second most common type of cerebral small vessel disease. CAA is usually caused by deposition of beta-amyloid in small arteries and arterioles in the leptomeninges and cerebral cortex. Rare genetic causes of CAA are marked by deposition of other types of amyloid [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">One of the most prominent changes in CAA is a loss of vascular integrity resulting in both large, symptomatic and small, asymptomatic brain hemorrhages (<a class="graphic graphic_diagnosticimage graphicRef119376" href="/d/graphic/119376.html" rel="external">image 1</a>). Hemorrhages are restricted to typical locations in the cortex or subcortical white matter (also called "lobar" locations) with sparing of the basal ganglia and brainstem [<a href="#rid41">41,42</a>]. Although the reason for this distinct distribution of vascular changes is not known, it has been exploited to derive CAA diagnostic criteria based on hemorrhage location (<a class="graphic graphic_table graphicRef139328" href="/d/graphic/139328.html" rel="external">table 2</a>) [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/1128.html" rel="external">"Cerebral amyloid angiopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others – There are many other less common or rare causes of cerebral small vessel disease, including genetic disorders such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), small vessel vasculitides and other inflammatory disorders, and venous collagenosis [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/1091.html" rel="external">"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)"</a>.)</p><p></p><p>Although consensus diagnostic criteria emphasize the role of vascular brain injury from ischemia or hemorrhage in producing vascular dementia, the cerebral vasculature does more than just deliver blood [<a href="#rid30">30,44,45</a>]. As a neurovascular unit, the blood vessels function in a harmonious, tightly integrated fashion along with pericytes, astrocytes, microglia, and neurons to support brain activity [<a href="#rid45">45,46</a>]. Supportive functions include maintaining blood-brain barrier permeability, trafficking of immune cells into and out of the brain, secretion of trophic factors, and clearing the brain of wastes. It is possible, but unproven, that loss of these vascular functions may play a role in causing vascular dementia or even other neurodegenerative diseases such as Alzheimer disease (AD) [<a href="#rid47">47-49</a>]. (See  <a class="medical medical_review" href="/d/html/16575.html" rel="external">"Epidemiology, pathology, and pathogenesis of Alzheimer disease", section on 'Cerebrovascular disease'</a>.)</p><p class="headingAnchor" id="H3882185972"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The essential feature of vascular dementia is disabling cognitive decline that is clinically attributed to a vascular cause. There are two main syndromes of vascular dementia: poststroke dementia and vascular dementia without recent stroke.</p><p class="headingAnchor" id="H307595330"><span class="h2">Poststroke dementia</span><span class="headingEndMark"> — </span>Patients with poststroke dementia experience a stepwise cognitive decline following a clinically diagnosed stroke. The link between cerebrovascular disease and the onset of cognitive impairment is thus relatively clear in most cases. </p><p>The cognitive profile of poststroke dementia is often marked by prominent impairment of executive functions, sometimes with relative sparing of episodic memory [<a href="#rid50">50</a>]. It may be accompanied by other cortical signs of stroke including aphasia and apraxia. However, there is wide interindividual variation in the cognitive profile, related in part to the heterogeneity in stroke location and size.</p><p>Not all patients exhibit the classic syndrome of disproportionate executive function impairment. For example, anterior thalamic infarction can cause isolated memory impairment with preservation of other domains, which could mimic the cognitive profile of Alzheimer disease (AD) [<a href="#rid51">51</a>].</p><p>Several patterns of stroke-related brain injury have been associated with vascular dementia and have been categorized as [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multi-infarct (or multi-hemorrhage) dementia – Damage to multiple brain regions has the cumulative effect of disrupting brain function, resulting in clinically significant cognitive impairment. Attempts to identify a threshold of infarct volume that predicts poststroke dementia have failed, with inconsistent results across studies. The inability to identify a threshold probably relates to variation in cognitive and brain reserve among individuals and inadequate consideration of the role of lesion location. Therefore, clinical judgment is needed to determine whether an individual pattern of vascular brain injury is sufficient to account for cognitive impairment. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Strategic infarction (or hemorrhage) – Damage to a single brain location can be sufficient to cause clinically significant cognitive impairment. Examples include the medial frontal lobes (anterior cerebral artery territory), language cortices, thalamus, and medial temporal lobes [<a href="#rid30">30</a>]. Using voxel-based lesion symptom mapping, a large study showed that infarction in the left frontotemporal lobes, left thalamus, and right parietal lobe were predictive of poststroke cognitive impairment [<a href="#rid52">52</a>]. In addition to stroke location and severity, factors related to cognitive and brain reserve influence the likelihood of poststroke dementia [<a href="#rid27">27,28</a>]. (See <a class="local">'Risk factors for poststroke dementia'</a> above.)</p><p></p><p>Cognitive impairment may improve as part of the stroke recovery process. After recovery, poststroke cognitive impairment may be static and nonprogressive if vascular risk factors are treated and there are no recurrent strokes. However, a systematic review identified that approximately 10 percent of patients develop new dementia one to four years after stroke [<a href="#rid27">27</a>], and population-based studies confirm that the average rate of cognitive decline accelerates after stroke [<a href="#rid53">53</a>]. </p><p>Up to half of the new dementia cases that occur more than one year after stroke are related to new, recurrent strokes [<a href="#rid27">27</a>]. The rest of the new dementia cases, related to progressive cognitive symptoms, are likely due to progressive cerebral small vessel disease and not AD, according to a cohort study that included beta-amyloid imaging [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H2047173228"><span class="h2">Vascular dementia without recent stroke</span><span class="headingEndMark"> — </span>Vascular dementia can also manifest as a progressive or stepwise cognitive decline without a concurrent history of symptomatic stroke, but with imaging evidence of clinically unrecognized cerebrovascular disease. Although frequently called "silent," this clinically unrecognized cerebrovascular disease is better termed "covert" because it is associated with lower cognitive performance and elevated risk for dementia [<a href="#rid55">55-57</a>]. (See <a class="local">'Etiology and pathophysiology'</a> above.)</p><p>The cognitive profile of arteriolosclerotic cerebral small vessel disease is marked by prominent impairment in executive function and processing speed [<a href="#rid58">58</a>]. Impairment is not exclusive to these domains, however, and more global impairments in memory and other functions can occur [<a href="#rid59">59</a>]. Compared with patients with AD, patients with vascular cognitive impairment (VCI) tend to have better verbal learning and recall, on average, and worse executive function. (See <a class="local">'Neuropsychological testing'</a> below.)</p><p>Cognitive impairment can progress in a series of stepwise declines, suggesting unrecognized strokes, or can be smooth and progressive [<a href="#rid60">60</a>], mimicking the course of a neurodegenerative disease [<a href="#rid32">32,34</a>]. Synonyms for this vascular dementia syndrome include Binswanger disease and subcortical ischemic vascular dementia. (See <a class="local">'Etiology and pathophysiology'</a> above.)</p><p>Cerebral small vessel disease due to cerebral amyloid angiopathy (CAA) can cause cognitive impairment in the absence of hemorrhagic stroke [<a href="#rid61">61,62</a>]. The typical cognitive profile of CAA is similar to that of arteriosclerotic cerebral small vessel disease, with impaired executive function and processing speed [<a href="#rid63">63,64</a>]. On average, episodic memory is not impaired to the same degree as in AD, even though it may not be normal [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/1128.html" rel="external">"Cerebral amyloid angiopathy", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H704364833"><span class="h2">Neuropsychiatric and motor signs</span><span class="headingEndMark"> — </span>Vascular dementia may be accompanied by neuropsychiatric signs such as depression, abulia, apathy, and psychosis with delusions or hallucinations [<a href="#rid65">65-68</a>]. Patients may exhibit pathologic laughing or crying, a phenomenon known as pseudobulbar affect [<a href="#rid69">69</a>]. Slowing of gait is common in patients with cerebral small vessel disease [<a href="#rid70">70</a>] and may lead to a syndrome described as lower body parkinsonism [<a href="#rid71">71</a>]. Increased urinary frequency may be seen [<a href="#rid72">72</a>].</p><p>Symptoms and signs related to past history of stroke may also be present, including aphasia, motor weakness, and sensory impairments [<a href="#rid70">70</a>]. (See <a class="local">'Poststroke dementia'</a> above.)</p><p class="headingAnchor" id="H2000999349"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Vascular dementia must be distinguished from other causes of acquired cognitive decline in older adults. However, it is important to remember that many dementias are due to multiple etiologies, of which vascular disease is one of the most common contributors. Brain imaging is useful to identify signs of silent (also called covert) cerebrovascular brain injury, which indicates a vascular contribution to the dementia. (See <a class="local">'Neuroimaging'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alzheimer disease</strong> – Alzheimer disease (AD) produces a gradual, progressive decline that can be mimicked by progressive cerebral small vessel disease. However, the typical cognitive profile of AD differs from vascular dementia in that there is usually more prominent impairment in episodic memory [<a href="#rid73">73</a>]. Atypical presentations of AD, such as the frontal variant, can make it difficult to distinguish from vascular dementia. (See  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Cardinal symptoms'</a>.)</p><p></p><p class="bulletIndent1">In most cases, clinical history and routine neuroimaging are probably sufficient to make a clinical diagnosis of vascular dementia, AD, or multiple-etiology dementia due to vascular dementia and AD. The Hachinski ischemic score is a simple clinical tool that uses elements of the history and routine physical examination to help predict the likelihood of vascular dementia or a vascular contribution to multiple-etiology dementia. (See <a class="local">'History'</a> below.) </p><p></p><p class="bulletIndent1">Amyloid positron emission tomography (PET) or measurements of beta-amyloid and phosphorylated tau in the cerebrospinal fluid determine the presence or absence of AD pathology with high sensitivity and specificity but are expensive and may not be available or practical in many clinical settings. On 18-F fluorodeoxyglucose (FDG) PET, a typical pattern of parietal and temporal hypometabolism suggests the presence of AD pathology, whereas the pattern of hypometabolism is more patchy and heterogeneous in patients with vascular dementia. (See  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Neuroimaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parkinson disease and other related dementias</strong> – Lewy body diseases (eg, Parkinson disease, dementia with Lewy bodies) produce a gradual, progressive decline with symptoms of gait-slowing that can mimic the progressive cognitive and gait impairment seen in cerebral small vessel disease. Vascular parkinsonism differs from Parkinson disease and other Lewy body diseases in that bradykinesia affects the legs more than the arms ("lower-body parkinsonism") and, in contrast to Parkinson disease, there is no resting tremor [<a href="#rid71">71</a>]. The presence of rapid eye movement (REM) sleep behavior disorder, fluctuations in level of alertness, and prominent visuospatial dysfunction favor dementia with Lewy bodies as the cause of or contributor to the dementia [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/5089.html" rel="external">"Cognitive impairment and dementia in Parkinson disease", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies", section on 'Core clinical features'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal pressure hydrocephalus</strong> – Normal pressure hydrocephalus (NPH) produces decline in cognition, slowed gait, and urinary incontinence that can mimic symptoms of progressive cerebral small vessel disease. The cognitive profile is similar to vascular dementia, with prominently impaired executive function presumed due to pressure on periventricular white matter tracts from the frontal lobes [<a href="#rid75">75</a>]. Both NPH and vascular dementia are associated with slowed gait, but the classic gait sign in NPH is an apraxic, wide-based "magnetic" gait [<a href="#rid76">76</a>]. In cerebral small vessel disease, the gait base is narrower and more closely resembles the gait disorder seen in parkinsonism. (See  <a class="medical medical_review" href="/d/html/5069.html" rel="external">"Normal pressure hydrocephalus"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Depression</strong> – Patients with depression may exhibit apathy, psychomotor slowing, and executive dysfunction that mimic the neuropsychological profile of vascular dementia. However, when the onset of depression is in later life (after age 50), clinicians must also consider whether depression is the initial manifestation of neurodegeneration or vascular cognitive impairment (VCI), rather than an alternative diagnosis. The syndrome of mild behavioral impairment defines patients with later-life newly acquired neurobehavioral symptoms that raise suspicion for neurodegeneration [<a href="#rid77">77</a>]. Late-life depression is associated with higher burden of magnetic resonance imaging (MRI)-defined silent cerebrovascular disease and confers increased risk for future diagnosis of vascular dementia, as well as all-cause dementia [<a href="#rid78">78,79</a>]. The evaluation and diagnosis of late-life depression are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.) </p><p></p><p class="headingAnchor" id="H3602055877"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of patients with suspected vascular dementia should focus on the severity and profile of cognitive decline, any clinical history of stroke, risk factors and causes of stroke or silent cerebrovascular disease, brain imaging evidence of silent cerebrovascular disease, and the presence of clinical features or biomarkers of other neurodegenerative diseases that might be an alternative or accompanying cause of dementia.</p><p class="headingAnchor" id="H4217749308"><span class="h2">History</span><span class="headingEndMark"> — </span>The history should focus on identifying the time course of cognitive decline and its relationship to basic and instrumental activities of daily living. Prior history of stroke should be ascertained, as well as its timing relative to the onset of cognitive symptoms. </p><p>The Hachinski ischemic score uses information from the past medical history, cognitive course, psychiatric symptoms, and neurologic examination to predict the likelihood of a vascular contribution to dementia [<a href="#rid80">80</a>]. If present, each of the following features is assigned two points:</p><p class="bulletIndent1"><span class="glyph">●</span>Abrupt onset</p><p class="bulletIndent1"><span class="glyph">●</span>Fluctuating course</p><p class="bulletIndent1"><span class="glyph">●</span>History of stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Focal neurologic symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Focal neurologic signs</p><p></p><p>The remaining features are each assigned one point: </p><p class="bulletIndent1"><span class="glyph">●</span>Stepwise deterioration</p><p class="bulletIndent1"><span class="glyph">●</span>Nocturnal confusion</p><p class="bulletIndent1"><span class="glyph">●</span>Preservation of personality</p><p class="bulletIndent1"><span class="glyph">●</span>Depression</p><p class="bulletIndent1"><span class="glyph">●</span>Somatic complaints</p><p class="bulletIndent1"><span class="glyph">●</span>Emotional incontinence (pseudobulbar affect)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Associated atherosclerosis</p><p></p><p>A score of 7 or greater indicates that a vascular contribution is likely. The score has been validated against autopsy data and accurately discriminates pure or mixed vascular dementia from pure Alzheimer disease (AD) dementia [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H2753150181"><span class="h2">Cognitive screening tests</span><span class="headingEndMark"> — </span>A cognitive screen should be performed to identify whether there is objective evidence of cognitive impairment, required for a diagnosis of mild cognitive impairment (MCI) or dementia. The Montreal Cognitive Assessment (MoCA) [<a href="#rid82">82</a>] is a 10-minute, 30-point cognitive screening instrument that seems to be more sensitive than the Folstein Mini-Mental State Examination for detecting vascular cognitive impairment (VCI) [<a href="#rid83">83</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmocacognition.com%2F&amp;token=b1YIhadNeg05BKW8lyJLG6R8uyFrFmc0HH66MOxJEZUbNyex33RJEu89nNTONJ3l&amp;TOPIC_ID=5085" target="_blank">MoCA</a> is available online and in multiple languages.</p><p>Although cutoffs are variably defined and scores are not meant to substitute for an integrated clinical diagnosis, MoCA scores of 25 and below are generally considered abnormal. Use of the MoCA and other screening tools in the evaluation of cognitive impairment is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Cognitive testing'</a>.)</p><p class="headingAnchor" id="H1825086702"><span class="h2">Neuropsychological testing</span><span class="headingEndMark"> — </span>Neuropsychological testing is suggested when the severity or pattern of cognitive dysfunction remains unclear despite a cognitive screening test and neurologic examination.</p><p>Compared with normative scores, patients with VCI on average have the greatest impairments in speed, praxis, executive function, and visual memory, with less prominent impairment in verbal episodic memory [<a href="#rid50">50</a>]. When patients with similar degrees of global cognitive dysfunction due to either vascular dementia or AD are compared, those with vascular dementia display better average performance on tests of verbal learning and recall and worse average performance on tests of frontal executive function (eg, Wisconsin card sorting task) [<a href="#rid84">84</a>]. Performance on tests of language, constructional abilities, memory registration, conceptual function, and attention and tracking tends to be similar.</p><p>Limitations of most studies include lack of biomarker confirmation of AD pathology and lack of derived thresholds for calculation of sensitivity and specificity. One study with autopsy confirmation found that a combination of better categorical than phonemic fluency and better word list recall differentiated vascular dementia from AD with a sensitivity of 85 percent and specificity of 67 percent; however, the sample sizes were small [<a href="#rid85">85</a>]. When interpreting neuropsychological test profiles, clinicians must keep in mind that vascular dementia is a highly heterogenous syndrome, and individual patients may have a cognitive profile that overlaps with AD.</p><p class="headingAnchor" id="H3150387008"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical examination should seek to identify evidence of gait impairment, bradykinesia, rigidity, hyperreflexia, and focal signs to suggest the presence of cerebral small vessel disease or stroke. (See  <a class="medical medical_review" href="/d/html/5095.html" rel="external">"The detailed neurologic examination in adults"</a>.)</p><p class="headingAnchor" id="H2770421555"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Laboratory evaluation should consist of electrolytes, creatinine, calcium, liver enzymes, complete blood count, vitamin B12, and thyroid-stimulating hormone to exclude causative or contributing metabolic or endocrine disorders.</p><p class="headingAnchor" id="H645631493"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Structural brain imaging should be performed to identify clinically unrecognized silent cerebrovascular disease as a contributor to cognitive decline and is useful to confirm the presence of infarction or hemorrhage in patients with a clinical history of stroke [<a href="#rid45">45,86</a>].</p><p>MRI is more sensitive than computed tomography (CT) for signs of cerebral small vessel disease, including microbleeds that can point to a diagnosis of cerebral amyloid angiopathy (CAA). MRI is therefore preferred over CT unless there are cost constraints or contraindications to MRI, although MRI is unlikely to identify a treatable cause of dementia not visualized on CT.</p><p>Standards for Reporting Vascular Changes on Neuroimaging (STRIVE) criteria provide radiologic definitions and terms for brain changes due to cerebral small vessel disease (<a class="graphic graphic_figure graphicRef118564" href="/d/graphic/118564.html" rel="external">figure 1</a>) [<a href="#rid2">2</a>]. These criteria are endorsed in an American Heart Association statement on stroke prevention in patients with silent cerebrovascular disease [<a href="#rid87">87</a>]. The best described signs are [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonlacunar infarcts – Infarcts &gt;15 mm or infarcts of any size in the cerebral cortex (<a class="graphic graphic_diagnosticimage graphicRef119373" href="/d/graphic/119373.html" rel="external">image 2</a>). These infarcts may result from cardioembolic sources. Cortical infarcts &lt;5 mm in size are also termed microinfarcts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lacunes of presumed vascular origin – Small, ≤15 mm infarcts in the subcortical brain regions (<a class="graphic graphic_diagnosticimage graphicRef119394" href="/d/graphic/119394.html" rel="external">image 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>White matter hyperintensities (on MRI) or hypodensities (on CT) of presumed vascular origin – Areas of increased water signal in the white matter, corresponding to areas of demyelination, axon loss, and oligodendrocyte loss (<a class="graphic graphic_diagnosticimage graphicRef119375" href="/d/graphic/119375.html" rel="external">image 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microbleeds – Small (&lt;10 mm) rounded areas of signal loss (hypointensity) on MRI susceptibility-weighted sequences, corresponding to areas of hemosiderin deposition (<a class="graphic graphic_diagnosticimage graphicRef119376" href="/d/graphic/119376.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Superficial siderosis – Linear hypointensity along the cortical surface visible on MRI susceptibility-weighted sequences. When it is seen along single or multiple supratentorial gyri, it is usually a sign of CAA, although other causes of superficial bleeding (eg, vascular malformations or cortical venous thrombosis) need to be excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perivascular spaces – Although not typically reported in routine radiologic practice, perivascular spaces become more visible in patients with cerebral small vessel diseases (<a class="graphic graphic_diagnosticimage graphicRef119377" href="/d/graphic/119377.html" rel="external">image 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrophy – Cerebral small vessel disease is associated with accelerated brain atrophy.</p><p></p><p class="headingAnchor" id="H1351213703"><span class="h2">Evaluation for causes of cerebrovascular disease</span><span class="headingEndMark"> — </span>An assessment of vascular risk factors and causes of stroke is necessary to implement targeted secondary prevention for recurrent stroke.</p><p>A scientific statement from the American Heart Association provides suggestions for investigations for patients with silent cerebrovascular disease [<a href="#rid87">87</a>]. At minimum, these investigations should include:</p><p class="bulletIndent1"><span class="glyph">●</span>A history of behavioral and lifestyle risks (smoking, diet, and obesity)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure measurement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An assessment of pulse for evidence of atrial fibrillation</p><p></p><p>In patients with embolic-appearing silent infarcts, it is reasonable to perform cardiac rhythm monitoring such as a 24-hour Holter monitor. In addition, if the embolic-appearing infarcts are in the perfusion territory of the carotid artery and the patient would be a candidate for carotid revascularization, it is reasonable to also obtain noninvasive vascular imaging of the carotid arteries to rule out carotid stenosis [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p><p class="headingAnchor" id="H3319755602"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Consensus diagnostic criteria for vascular dementia have been offered by several organizations: the American Heart Association [<a href="#rid45">45</a>], the Diagnostic and Statistical Manual of Mental Disorders,<sup> </sup>Fifth Edition (DSM-5) [<a href="#rid44">44</a>], and the International Society of Vascular Behavioural and Cognitive Disorders (VAS-COG) [<a href="#rid30">30</a>]. </p><p>The diagnostic criteria are conceptually similar (<a class="graphic graphic_table graphicRef118562" href="/d/graphic/118562.html" rel="external">table 3</a>). Common elements include [<a href="#rid30">30,44,45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Classification of vascular cognitive impairment (VCI) as either vascular mild cognitive impairment (MCI; referred to as "vascular minor neurocognitive disorder" in DSM-5) or vascular dementia (vascular major neurocognitive disorder)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A requirement that cerebrovascular disease be identified either by history of stroke or by neuroimaging identification of silent cerebrovascular disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A judgment that the cerebrovascular disease be considered sufficient to cause cognitive impairment</p><p></p><p>Cognitive impairment should be categorized as either MCI (mild neurocognitive disorder) or dementia (major neurocognitive disorder) [<a href="#rid30">30,44,45</a>]. In contrast to older criteria, some of the newer criteria specify that significant impairment in only one domain can be considered sufficient to diagnose MCI or dementia, and do not require that memory be one of the affected domains [<a href="#rid30">30,44</a>]. MCI is distinguished from dementia primarily by a relative preservation of functioning. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Criteria for dementia'</a> and  <a class="medical medical_review" href="/d/html/5081.html" rel="external">"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment", section on 'Definitions'</a>.)</p><p>Assessing cognition and cognitive-related functional decline can be challenging when there are additional effects of stroke present. Severe aphasia may prevent assessment of any cognitive abilities other than language itself. However, all of the modern diagnostic criteria specify that poststroke dementia can be diagnosed when aphasia prevents independent function in activities of daily living [<a href="#rid30">30,44,45</a>]. When assessing the impact of cognition on function, clinical judgment may be required to separate the impact of cognitive impairment from the impact of motor and sensory impairments after stroke.</p><p>In all criteria, a history of stroke followed by new onset of dementia is sufficient proof of a vascular cause [<a href="#rid30">30,44,45</a>]. The clinician should obtain a retrospective history to verify the presence or absence of cognitive decline prior to stroke, which, if present, suggests that there is an additional superimposed neurodegenerative disease present or progressive cerebral small vessel disease. In most cases, clinical history and routine neuroimaging are probably sufficient to make a clinical diagnosis of vascular dementia, Alzheimer disease (AD), or multiple-etiology dementia with vascular dementia and AD. (See <a class="local">'Differential diagnosis'</a> above.) </p><p>All criteria specify that a high burden of clinically unrecognized silent cerebrovascular disease can be sufficient to cause dementia [<a href="#rid30">30,44,45</a>]. The American Heart Association criteria call this syndrome "diffuse, subcortical cerebrovascular disease pathology" [<a href="#rid45">45</a>]. The VAS-COG criteria provide the most specific criteria for burden of silent cerebrovascular disease that may be sufficient to cause VCI [<a href="#rid30">30</a>]. According to these criteria, one to two large vessel infarcts, a single large or strategically placed infarct, multiple lacunar infarcts (&gt;2) outside the brainstem, one to two strategically placed lacunes alone or in combination with extensive white matter lesions, or extensive and confluent white matter lesions of presumed vascular origin may be considered sufficient to cause vascular MCI or dementia [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H3725770481"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.) </p><p class="headingAnchor" id="H564534186"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Vascular dementia refers to any dementia that is primarily caused by cerebrovascular disease or impaired cerebral blood flow, or in which cerebrovascular disease or impaired cerebral blood flow is a contributing causative factor. (See <a class="local">'Definitions'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Vascular disease is a cause or contributor in 25 to 50 percent of cases of dementia, and vascular dementia is the second most common type of dementia. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Vascular dementia is caused by diseases of the cerebral vasculature and of the cardiovascular system, including hypoperfusion and embolism from the heart. Any cause of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage can cause vascular dementia if the resulting brain injury is severe enough (<a class="graphic graphic_table graphicRef118574" href="/d/graphic/118574.html" rel="external">table 1</a>). In addition, cerebral small vessel diseases play an outsized role in the burden of vascular dementia. (See <a class="local">'Etiology and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical syndromes</strong> – There are two main syndromes of vascular dementia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Poststroke dementia</strong> – These patients experience a stepwise cognitive decline following a clinically diagnosed stroke. The cognitive profile is often marked by prominent impairment of executive functions, sometimes with relative sparing of episodic memory. It may be accompanied by other cortical signs of stroke including aphasia and apraxia. (See <a class="local">'Poststroke dementia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vascular dementia without recent stroke</strong> – These patients experience progressive or stepwise cognitive decline with prominent impairment in executive function and processing speed. Brain imaging shows evidence of cerebrovascular disease. (See <a class="local">'Vascular dementia without recent stroke'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of vascular dementia includes other causes of acquired cognitive decline in older adults, such as Alzheimer disease (AD), Lewy body diseases, and normal pressure hydrocephalus (NPH).</p><p></p><p class="bulletIndent1">However, it is important to remember that many dementias are due to multiple etiologies, of which vascular disease is one of the most common contributors. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The evaluation of patients with suspected vascular dementia should focus on the severity and profile of cognitive decline, any clinical history of stroke, risk factors and causes of stroke or silent cerebrovascular disease, and the presence of clinical features or biomarkers of other neurodegenerative diseases that might be an alternative or accompanying cause of dementia. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Brain imaging, usually MRI, should be performed to identify clinically unrecognized silent cerebrovascular disease as a contributor to cognitive decline and is useful to confirm the presence of infarction or hemorrhage in patients with a clinical history of stroke (<a class="graphic graphic_figure graphicRef118564" href="/d/graphic/118564.html" rel="external">figure 1</a>). (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In most cases, clinical history and neuroimaging are sufficient to make a clinical diagnosis of vascular dementia, AD, or multiple-etiology dementia with vascular dementia and AD. Several organizations have published consensus diagnostic criteria for vascular dementia (<a class="graphic graphic_table graphicRef118562" href="/d/graphic/118562.html" rel="external">table 3</a>). Three common elements include the following (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Classification of vascular cognitive impairment (VCI) as either vascular mild cognitive impairment (MCI; also referred to as "vascular minor neurocognitive disorder") or vascular dementia (vascular major neurocognitive disorder).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A requirement that cerebrovascular disease be identified either by history of stroke or by neuroimaging identification of silent cerebrovascular disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A judgment that the cerebrovascular disease be considered sufficient to cause cognitive impairment.</p><p></p><p class="headingAnchor" id="H865715804"><span class="h1">ACKNOWLEDGEMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the views of the National Institutes of Health, the Department of Health and Human Services, or the United States government.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357:169.</a></li><li><a class="nounderline abstract_t">Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12:822.</a></li><li><a class="nounderline abstract_t">Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6:611.</a></li><li><a class="nounderline abstract_t">Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond) 2017; 131:1059.</a></li><li><a class="nounderline abstract_t">Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37:2220.</a></li><li><a class="nounderline abstract_t">Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69:2197.</a></li><li><a class="nounderline abstract_t">Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 2014; 13:614.</a></li><li><a class="nounderline abstract_t">Feldman H, Levy AR, Hsiung GY, et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology 2003; 22:265.</a></li><li><a class="nounderline abstract_t">Matthews FE, Brayne C, Lowe J, et al. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 2009; 6:e1000180.</a></li><li><a class="nounderline abstract_t">Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007; 62:406.</a></li><li><a class="nounderline abstract_t">Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54:S4.</a></li><li><a class="nounderline abstract_t">Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med 2016; 374:523.</a></li><li><a class="nounderline abstract_t">Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66:200.</a></li><li><a class="nounderline abstract_t">Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349:1793.</a></li><li><a class="nounderline abstract_t">Wentzel C, Rockwood K, MacKnight C, et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology 2001; 57:714.</a></li><li><a class="nounderline abstract_t">Sharp SI, Aarsland D, Day S, et al. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011; 26:661.</a></li><li><a class="nounderline abstract_t">Hébert R, Lindsay J, Verreault R, et al. Vascular dementia : incidence and risk factors in the Canadian study of health and aging. Stroke 2000; 31:1487.</a></li><li><a class="nounderline abstract_t">Hassing LB, Johansson B, Nilsson SE, et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 2002; 14:239.</a></li><li><a class="nounderline abstract_t">Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61:705.</a></li><li><a class="nounderline abstract_t">Aarsland D, Sardahaee FS, Anderssen S, et al. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 2010; 14:386.</a></li><li><a class="nounderline abstract_t">Xu WL, Atti AR, Gatz M, et al. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011; 76:1568.</a></li><li><a class="nounderline abstract_t">Rusanen M, Kivipelto M, Quesenberry CP Jr, et al. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 2011; 171:333.</a></li><li><a class="nounderline abstract_t">Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28:316.</a></li><li><a class="nounderline abstract_t">Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 2010; 7:433.</a></li><li><a class="nounderline abstract_t">Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke 2014; 45:315.</a></li><li><a class="nounderline abstract_t">Murray AD, Staff RT, McNeil CJ, et al. The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. Brain 2011; 134:3687.</a></li><li><a class="nounderline abstract_t">Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8:1006.</a></li><li><a class="nounderline abstract_t">Liu W, Wong A, Au L, et al. Influence of Amyloid-β on Cognitive Decline After Stroke/Transient Ischemic Attack: Three-Year Longitudinal Study. Stroke 2015; 46:3074.</a></li><li><a class="nounderline abstract_t">Iadecola C. The pathobiology of vascular dementia. Neuron 2013; 80:844.</a></li><li><a class="nounderline abstract_t">Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 2014; 28:206.</a></li><li><a class="nounderline abstract_t">White L, Petrovitch H, Hardman J, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 2002; 977:9.</a></li><li><a class="nounderline abstract_t">Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:689.</a></li><li><a class="nounderline abstract_t">Furuta A, Ishii N, Nishihara Y, Horie A. Medullary arteries in aging and dementia. Stroke 1991; 22:442.</a></li><li><a class="nounderline abstract_t">Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997; 28:652.</a></li><li><a class="nounderline abstract_t">Román GC. Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. JAMA 1987; 258:1782.</a></li><li><a class="nounderline abstract_t">Román GC, Erkinjuntti T, Wallin A, et al. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1:426.</a></li><li><a class="nounderline abstract_t">Skrobot OA, O'Brien J, Black S, et al. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement 2017; 13:624.</a></li><li><a class="nounderline abstract_t">Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 2012; 11:272.</a></li><li><a class="nounderline abstract_t">Duering M, Righart R, Csanadi E, et al. Incident subcortical infarcts induce focal thinning in connected cortical regions. Neurology 2012; 79:2025.</a></li><li><a class="nounderline abstract_t">Revesz T, Holton JL, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 2009; 118:115.</a></li><li><a class="nounderline abstract_t">Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983; 14:924.</a></li><li><a class="nounderline abstract_t">Gilbert JJ, Vinters HV. Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage. Stroke 1983; 14:915.</a></li><li><a class="nounderline abstract_t">Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol 2022; 21:714.</a></li><li class="breakAll">Diagnostic and Statistical Manual of Mental Disorders, 5th ed, American Psychiatric Association, Washington, DC 2013.</li><li><a class="nounderline abstract_t">Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:2672.</a></li><li><a class="nounderline abstract_t">Demuth HU, Dijkhuizen RM, Farr TD, et al. Recent progress in translational research on neurovascular and neurodegenerative disorders. Restor Neurol Neurosci 2017; 35:87.</a></li><li><a class="nounderline abstract_t">Bakker EN, Bacskai BJ, Arbel-Ornath M, et al. Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative Diseases. Cell Mol Neurobiol 2016; 36:181.</a></li><li><a class="nounderline abstract_t">Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330:1774.</a></li><li><a class="nounderline abstract_t">Iturria-Medina Y, Sotero RC, Toussaint PJ, et al. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun 2016; 7:11934.</a></li><li><a class="nounderline abstract_t">Sachdev PS, Brodaty H, Valenzuela MJ, et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 2004; 62:912.</a></li><li><a class="nounderline abstract_t">Meguro K, Akanuma K, Ouchi Y, et al. Vascular dementia with left thalamic infarction: neuropsychological and behavioral implications suggested by involvement of the thalamic nucleus and the remote effect on cerebral cortex. The Osaki-Tajiri project. Psychiatry Res 2013; 213:56.</a></li><li><a class="nounderline abstract_t">Weaver NA, Kuijf HJ, Aben HP, et al. Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts. Lancet Neurol 2021; 20:448.</a></li><li><a class="nounderline abstract_t">Reitz C, Bos MJ, Hofman A, et al. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke 2008; 39:36.</a></li><li><a class="nounderline abstract_t">Mok VCT, Lam BYK, Wang Z, et al. Delayed-onset dementia after stroke or transient ischemic attack. Alzheimers Dement 2016; 12:1167.</a></li><li><a class="nounderline abstract_t">Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:1215.</a></li><li><a class="nounderline abstract_t">Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010; 41:600.</a></li><li><a class="nounderline abstract_t">Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33:21.</a></li><li><a class="nounderline abstract_t">Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 341:c3666.</a></li><li><a class="nounderline abstract_t">de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000; 47:145.</a></li><li><a class="nounderline abstract_t">Amberla K, Wäljas M, Tuominen S, et al. Insidious cognitive decline in CADASIL. Stroke 2004; 35:1598.</a></li><li><a class="nounderline abstract_t">Moulin S, Labreuche J, Bombois S, et al. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. Lancet Neurol 2016; 15:820.</a></li><li><a class="nounderline abstract_t">Boyle PA, Yu L, Nag S, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 2015; 85:1930.</a></li><li><a class="nounderline abstract_t">Case NF, Charlton A, Zwiers A, et al. Cerebral Amyloid Angiopathy Is Associated With Executive Dysfunction and Mild Cognitive Impairment. Stroke 2016; 47:2010.</a></li><li><a class="nounderline abstract_t">Xiong L, Davidsdottir S, Reijmer YD, et al. Cognitive Profile and its Association with Neuroimaging Markers of Non-Demented Cerebral Amyloid Angiopathy Patients in a Stroke Unit. J Alzheimers Dis 2016; 52:171.</a></li><li><a class="nounderline abstract_t">Park JH, Lee SB, Lee TJ, et al. Depression in vascular dementia is quantitatively and qualitatively different from depression in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23:67.</a></li><li><a class="nounderline abstract_t">Moretti R, Torre P, Antonello RM, Cazzato G. Behavioral alterations and vascular dementia. Neurologist 2006; 12:43.</a></li><li><a class="nounderline abstract_t">Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia. J Neurol Neurosurg Psychiatry 2005; 76:1337.</a></li><li><a class="nounderline abstract_t">Ballard C, Neill D, O'Brien J, et al. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord 2000; 59:97.</a></li><li><a class="nounderline abstract_t">Foley K, Konetzka RT, Bunin A, Yonan C. Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents. Int J Geriatr Psychiatry 2016; 31:694.</a></li><li><a class="nounderline abstract_t">Staekenborg SS, van der Flier WM, van Straaten EC, et al. Neurological signs in relation to type of cerebrovascular disease in vascular dementia. Stroke 2008; 39:317.</a></li><li><a class="nounderline abstract_t">Thanvi B, Lo N, Robinson T. Vascular parkinsonism--an important cause of parkinsonism in older people. Age Ageing 2005; 34:114.</a></li><li><a class="nounderline abstract_t">Kotsoris H, Barclay LL, Kheyfets S, et al. Urinary and gait disturbances as markers for early multi-infarct dementia. Stroke 1987; 18:138.</a></li><li><a class="nounderline abstract_t">Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry 2004; 75:61.</a></li><li><a class="nounderline abstract_t">McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89:88.</a></li><li><a class="nounderline abstract_t">Saito M, Nishio Y, Kanno S, et al. Cognitive profile of idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Dis Extra 2011; 1:202.</a></li><li><a class="nounderline abstract_t">Gallia GL, Rigamonti D, Williams MA. The diagnosis and treatment of idiopathic normal pressure hydrocephalus. Nat Clin Pract Neurol 2006; 2:375.</a></li><li><a class="nounderline abstract_t">Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 2016; 12:195.</a></li><li><a class="nounderline abstract_t">Wang L, Leonards CO, Sterzer P, Ebinger M. White matter lesions and depression: a systematic review and meta-analysis. J Psychiatr Res 2014; 56:56.</a></li><li><a class="nounderline abstract_t">Diniz BS, Butters MA, Albert SM, et al. Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 2013; 202:329.</a></li><li><a class="nounderline abstract_t">Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32:632.</a></li><li><a class="nounderline abstract_t">Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997; 49:1096.</a></li><li><a class="nounderline abstract_t">Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695.</a></li><li><a class="nounderline abstract_t">Pendlebury ST, Mariz J, Bull L, et al. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke 2012; 43:464.</a></li><li><a class="nounderline abstract_t">Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999; 53:670.</a></li><li><a class="nounderline abstract_t">Ramirez-Gomez L, Zheng L, Reed B, et al. Neuropsychological Profiles Differentiate Alzheimer Disease from Subcortical Ischemic Vascular Dementia in an Autopsy-Defined Cohort. Dement Geriatr Cogn Disord 2017; 44:1.</a></li><li><a class="nounderline abstract_t">Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143.</a></li><li><a class="nounderline abstract_t">Smith EE, Saposnik G, Biessels GJ, et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2017; 48:e44.</a></li></ol></div><div id="topicVersionRevision">Topic 5085 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213093" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23867200" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582361" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Silent brain infarcts: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28515342" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical presentations and epidemiology of vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917086" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568013" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mixed brain pathologies account for most dementia cases in community-dwelling older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24849862" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902621" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901977" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879383" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pathological correlates of dementia in a longitudinal, population-based sample of aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10854354" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26863354" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence of Dementia over Three Decades in the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19743450" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The neuropathology of probable Alzheimer disease and mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269213" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence and severity of cognitive impairment with and without dementia in an elderly population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524488" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Progression of impairment in patients with vascular cognitive impairment without dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21495075" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypertension is a potential risk factor for vascular dementia: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884442" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vascular dementia : incidence and risk factors in the Canadian study of health and aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475085" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148148" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relation of plasma lipids to Alzheimer disease and vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20455113" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is physical activity a potential preventive factor for vascular dementia? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536637" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Midlife overweight and obesity increase late-life dementia risk: a population-based twin study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975015" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040682" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Atrial fibrillation and dementia in a population-based study. The Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122875" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309587" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22102649" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782001" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26382174" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Influence of Amyloid-βon Cognitive Decline After Stroke/Transient Ischemic Attack: Three-Year Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24267647" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The pathobiology of vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24632990" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480729" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610345" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024272" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Medullary arteries in aging and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9056627" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pathogenesis of leukoaraiosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3625988" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Senile dementia of the Binswanger type. A vascular form of dementia in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849365" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Subcortical ischaemic vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27960092" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Vascular Impairment of Cognition Classification Consensus Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341035" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cerebral microinfarcts: the invisible lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23054230" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incident subcortical infarcts induce focal thinning in connected cortical regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225789" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6658996" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6658995" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35841910" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35841910" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21778438" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28059802" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recent progress in translational research on neurovascular and neurodegenerative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26993512" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148344" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Decreased clearance of CNS beta-amyloid in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27327500" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037692" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23693088" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vascular dementia with left thalamic infarction: neuropsychological and behavioral implications suggested by involvement of the thalamic nucleus and the remote effect on cerebral cortex. The Osaki-Tajiri project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33901427" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006863" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27327542" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Delayed-onset dementia after stroke or transient ischemic attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660385" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Silent brain infarcts and the risk of dementia and cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167919" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779883" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660506" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665484" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15143298" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Insidious cognitive decline in CADASIL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133238" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26537052" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27338926" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cerebral Amyloid Angiopathy Is Associated With Executive Dysfunction and Mild Cognitive Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060947" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cognitive Profile and its Association with Neuroimaging Markers of Non-Demented Cerebral Amyloid Angiopathy Patients in a Stroke Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114882" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Depression in vascular dementia is quantitatively and qualitatively different from depression in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547446" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Behavioral alterations and vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170072" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837878" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Anxiety, depression and psychosis in vascular dementia: prevalence and associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526856" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096841" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neurological signs in relation to type of cerebrovascular disease in vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15713855" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Vascular parkinsonism--an important cause of parkinsonism in older people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3810746" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Urinary and gait disturbances as markers for early multi-infarct dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14707310" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592453" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22163245" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cognitive profile of idiopathic normal pressure hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932588" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The diagnosis and treatment of idiopathic normal pressure hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096665" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24948437" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : White matter lesions and depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23637108" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1164215" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cerebral blood flow in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9339696" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817019" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156700" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10489025" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Differentiation of vascular dementia from AD on neuropsychological tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28595184" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neuropsychological Profiles Differentiate Alzheimer Disease from Subcortical Ischemic Vascular Dementia in an Autopsy-Defined Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342678" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27980126" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
